This groundbreaking study explores the potential of regenerating damaged hearts using lab-grown engineered heart muscle (EHM) transplants derived from stem cells. The researchers implanted these EHM grafts into rhesus macaques with heart failure and found that the transplanted cells remained viable long-term, integrated functionally into the heart muscle, and improved cardiac performance. Key safety concerns, such as the risk of arrhythmias or uncontrolled cell growth, were carefully assessed, and no critical side effects were observed.
These findings paved the way for the approval of a first-in-human clinical trial. In an initial patient, the implanted EHM successfully integrated into the heart, supporting the clinical feasibility of this regenerative therapy for heart failure.
Link to the publication:
Engineered heart muscle allografts for heart repair in primates and humans (Jebran et al., Nature, 2025)
